These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

108 related articles for article (PubMed ID: 7061487)

  • 61. Antithrombin III Geneva: a hereditary abnormal AT III with defective heparin cofactor activity.
    de Moerloose PA; Reber G; Vernet P; Minazio P; Bouvier CA
    Thromb Haemost; 1987 Apr; 57(2):154-7. PubMed ID: 3603409
    [TBL] [Abstract][Full Text] [Related]  

  • 62. A kinetic analysis of the interaction of human recombinant tissue factor pathway inhibitor with factor Xa utilizing and immunoassay and the effect of antithrombin III/heparin on the complex formation.
    Kamikubo Y; Hamuro T; Takemoto S; Nakahara Y; Kamei S; Nakagaki T; Miyamoto S; Funatsu A; Kato H
    Thromb Res; 1998 Feb; 89(4):179-86. PubMed ID: 9651145
    [TBL] [Abstract][Full Text] [Related]  

  • 63. A new synthetic pentasaccharide with increased anti-factor Xa activity: possible role for anionic clusters in the interaction of heparin and antithrombin III.
    Petitou M; Lormeau JC; Choay J
    Semin Thromb Hemost; 1991; 17 Suppl 2():143-6. PubMed ID: 1948084
    [No Abstract]   [Full Text] [Related]  

  • 64. Interaction of heparin with antithrombin III and platelet factor 4: pH dependence demonstrated with a new rocket precipitin Electrophoretic procedure.
    Wohl H; Hinkley J; Krishnan L; Weekly L
    Anal Biochem; 1982 Sep; 125(2):433-41. PubMed ID: 7181101
    [No Abstract]   [Full Text] [Related]  

  • 65. Purification of antithrombin 'Vicenza': a molecule with normal heparin affinity and impaired reactivity to thrombin.
    Finazzi G; Tran TH; Barbui T; Duckert F
    Br J Haematol; 1985 Feb; 59(2):259-63. PubMed ID: 3970857
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Elimination of intravenously administered radiolabelled antithrombin III and heparin in humans.
    de Swart CA; Nijmeyer B; Andersson LO; Holmer E; Sixma JJ; Bouma BN
    Thromb Haemost; 1984 Aug; 52(1):66-70. PubMed ID: 6495266
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Metabolism of antithrombin III (heparin cofactor) in man: effects of venous thrombosis and of heparin administration.
    Collen D; Schetz J; de Cock F; Holmer E; Verstraete M
    Eur J Clin Invest; 1977 Feb; 7(1):27-35. PubMed ID: 65284
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Development of heparin fractions: some overlooked considerations.
    Fareed J
    Semin Thromb Hemost; 1985 Apr; 11(2):227-36. PubMed ID: 3898374
    [No Abstract]   [Full Text] [Related]  

  • 69. The acceleration of the inhibition of platelet prothrombinase complex by heparin.
    Ellis V; Scully MF; Kakkar VV
    Biochem J; 1986 Jan; 233(1):161-5. PubMed ID: 3954724
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Structure-activity relationship in heparin: a synthetic pentasaccharide with high affinity for antithrombin III and eliciting high anti-factor Xa activity.
    Choay J; Petitou M; Lormeau JC; Sinaÿ P; Casu B; Gatti G
    Biochem Biophys Res Commun; 1983 Oct; 116(2):492-9. PubMed ID: 6651824
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Role of the antithrombin-binding pentasaccharide in heparin acceleration of antithrombin-proteinase reactions. Resolution of the antithrombin conformational change contribution to heparin rate enhancement.
    Olson ST; Björk I; Sheffer R; Craig PA; Shore JD; Choay J
    J Biol Chem; 1992 Jun; 267(18):12528-38. PubMed ID: 1618758
    [TBL] [Abstract][Full Text] [Related]  

  • 72. The anti-heparin properties of human low-density lipoprotein.
    MacGregor IR; Lane DA; Kakkar VV
    Biochim Biophys Acta; 1980 Mar; 617(3):472-9. PubMed ID: 7189413
    [TBL] [Abstract][Full Text] [Related]  

  • 73. A rational approach to heparins.
    Hemker HC; Béguin S
    Nouv Rev Fr Hematol (1978); 1992; 34(1):5-9. PubMed ID: 1326098
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Pasteurisation induced changes in an antithrombin III concentrate.
    Winkelman L; Haddon ME
    Thromb Res; 1986 Jul; 43(2):219-27. PubMed ID: 3738862
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Anticoagulant activity of artificial biomedical materials with co-immobilized antithrombin III and heparin.
    Miura Y; Aoyagi S; Ikeda F; Miyamoto K
    Biochimie; 1980; 62(8-9):595-601. PubMed ID: 7417594
    [TBL] [Abstract][Full Text] [Related]  

  • 76. [Procedures for the isolation and characterization of human antithrombin III].
    Trobisch H; Wüst T; Rustige H
    Behring Inst Mitt; 1986 Feb; (79):177-90. PubMed ID: 3718405
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Preparation and characterization of monoclonal antibodies against the human thrombin-antithrombin III complex.
    Asakura S; Yoshida N; Matsuda M; Murayama H; Soe G
    Biochim Biophys Acta; 1988 Jan; 952(1):37-47. PubMed ID: 3422029
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Dissociation of complexes and their derivatives formed during inhibition of bovine thrombin and activated factor X by antithrombin III.
    Jesty J
    J Biol Chem; 1979 Feb; 254(4):1044-9. PubMed ID: 762113
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Practical considerations on the measurement of low molecular weight heparin anti-Xa activity.
    Aiach M; Roncato M
    Semin Thromb Hemost; 1985 Apr; 11(2):108-11. PubMed ID: 4035362
    [No Abstract]   [Full Text] [Related]  

  • 80. Formation, characterization and detection of a ternary complex between S protein, thrombin and antithrombin III in serum.
    Preissner KT; Zwicker L; Müller-Berghaus G
    Biochem J; 1987 Apr; 243(1):105-11. PubMed ID: 3606566
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.